System to promote translational research in cooperation with hospitals and research institute in National Cancer Center

Abstract

National Cancer Center (NCC) has recently developed a novel framework between hospitals and research institute (Tsukiji Translational Research Board: TTRB), and an organization in research institute (Fundamental Innovative Oncology Core: FIOC) to promote translational research (TR) and reverse TR (rTR) at Tsukiji campus in cooperation with pharmaceutical companies and academia. TTRB provides one stop service about consultation of research design and responsible researchers, and pharmaceutical companies can much easily access to relevant departments in hospitals and research institute. The direction of TR/rTR plan is rapidly determined by TTRB, which is communicated to FIOC. FIOC actually performs TR/rTR and supports the development of novel biomarkers and drugs, and pharmaceutical companies can easily reach clinical samples with detailed clinical information, original research findings, advanced and standard technologies and deep discussion with many experts in NCC reseach institute. During recent 16 months, already 20 TR/rTR studies have been conducted by TTRB, and hereafter this approach will increase more.